Overview
Asiri Surgical Hospital operates a private surgical hospital offering diagnostics, consultations and post-operative care across a range of specialist disciplines. The latest filing shows continued revenue and profit growth, with stable gross profitability, while the share price has diverged sharply from those operating results.
Price performance
AMSL closed at LKR 13.90 on 1 September 2026. It fell 29.6% over three months versus a 4.5% decline in the ASPI, while its six-month return of -9.8% was broadly in line with the index's -10.3% fall.
The price sat only 4.2% up from its 52-week low. Sixty-day volatility was below the company's own one-year level, while 20-day trading volume was above its 60-day norm. Nothing in the supplied filings or direct news flow establishes the cause of the three-month sell-off.
Valuation
At 8.67 times earnings, AMSL trades at a substantial discount to the healthcare peer median of 19.29 times. Its P/B of 0.994 is also below the sector median of 2.30, alongside a twelve-month ROE of 11.5%.
No current dividend yield is indicated. The most recent recorded distribution was LKR 0.30 per share for FY2025, with no dividend recorded for the two preceding financial years. A sector valuation percentile is not supplied, so the scale of the discount within the full peer distribution cannot be assessed.
News and sentiment
Direct coverage was normal, with two material articles over the past 90 days split evenly between positive and negative sentiment. One August article concerning Softlogic Holdings reported that an Asiri Surgical Hospital tax dispute was under appeal.
The supplied archive also contains two March enforcement-action notices, but provides no underlying detail on the matter.
Financials
June-quarter revenue grew 7.4% year-on-year and net profit rose 11.6%. Gross margin held at 43.2% year-on-year and was among the stronger June readings on record, while net margin widened from 10.7% to 11.1% but remained middling against prior June quarters.
Operating profit was not disclosed in the June filing, so an operating-margin comparison is unavailable. The audited year to March recorded a 151.6% increase in net profit. Equity increased year-on-year and the share count was unchanged, avoiding a mechanical per-share benefit from new shares.
Risks
The main financial risk is weak cash conversion: operating cash flow represented only 0.33 times operating profit in the year to March, and free cash flow was negative. This means the improvement in reported earnings was not fully realised in cash.
Debt was LKR 1.84 billion at the latest audited year-end, equal to gearing of 24.2% of owners' equity. Interest cover of 4.78 times provides headroom, but the current ratio of 1.09 leaves limited short-term liquidity headroom. Minority shareholders received 13.4% of group profit, so group profit is larger than the profit attributable to AMSL shareholders.
Outlook
As at 1 September 2026, the next scheduled catalyst is the September-quarter filing, expected between 11 November 2026 and 27 February 2027. It will update whether the June-quarter profit growth and cash-generation gap persisted.
The available data cannot determine the outcome or financial effect of the tax dispute under appeal. Falling Treasury yields in the broader market are potentially supportive of financing conditions, but the supplied data does not establish a direct effect on AMSL.